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Background and purpose: Anxiety is the most important precipitating factor of migraine attacks, and more than 
half of migraineurs have coexisting anxiety disorders. Paroxetine, an antidepressant, is one of the selective serotonin 
reuptake inhibitors (SSRIs) that has an anxiolytic effect, and is also known to be effective for migraine prophylaxis. 
The aim of this study was to determine the role of the anxiolytic effect of paroxetine on the prevention of migraine.
Methods: This study investigated migraineurs with a general anxiety disorder who visited the neurological clinic. 
The following efficacy variables were assessed at baseline and after taking paroxetine (20 for 12 weeks: headache 
frequency, Hamilton Anxiety Rating Scale (HAM-A), Headache Management Self-Efficacy Scale (HMSE), and 
Headache Disability Inventory (HDI). The correlation between the headache responsiveness to paroxetine and 
improvement in anxiety levels was analyzed.
Results: Twenty-four patients (aged 54.96±12.09 years, mean±SD) were included in this study. Paroxetine 
reduced headache frequency by 49.1% within 12 weeks (p<0.05 vs baseline). HAM-A and HMSE scores also 
showed an improvement, whereas there was no significant change in HDI score. The baseline HAM-A scores did 
not differ between paroxetine responders and nonresponders. In addition, the improvement in HAM-A score was not 
correlated with the reduction in headache frequency.
Conclusions: Paroxetine decreased the headache frequency and reduced anxiety levels. However, the anxiolytic 
effect of paroxetine was not correlated with the migraine prevention effect. These observation indicate that the 
anxiolytic effect of paroxetine does not contribute strongly to its prophylactic effect on migraine frequency in 
migraineurs with anxiety disorder.
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INTRODUCTION
Migraine is a common neurologic disorder, with 
reported prevalences of 10–12% in Western countries
1 
and 8.4–22.3% in Eastern countries.
2-4 Anxiety is one 
of the most important precipitating factors of migraine 
attacks and is commonly observed during prodrome 
or the migraine attack itself. The comorbidity rate of 
migraine and anxiety disorder has been reported in some Park HJ, et al. The Effect of Paroxetine on the Reduction of Migraine Frequency 
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studies to be more than 50%.
5-7
Antidepressants such as tricyclic antidepressants 
(TCAs), serotonin reuptake inhibitors (SSRIs), and 
serotonin norepinephrine reuptake inhibitors (SNRIs) 
exhibit some prophylactic effects against migraine, but 
the underlying mechanisms have not been defined.
8-10 
Because antidepressants usually have an anxiolytic 
effect, it has been suggested that the improvement in 
anxiety is related with the prevention of a migraine 
attack.
10 However, no previous study has shown that a 
migraine attack can be prevented by reducing anxiety 
levels.
Paroxetine, an SSRI, is used widely as an anti-
depressant or anxiolytic. While it has no GABAergic 
effects, it is 22 times more potent than fluoxetine, 7 
times thansertraline, and 80-100 times than amitriptyline 
or imipramine, respectively. In this study we determined 
the preventive effect of paroxetine for migraine, and 
assessed whether the anxiolytic effect of paroxetine is 
correlated with its prophylactic effect against migraine.
SUBJECTS AND METHODS
1. Subjects and study design
This study was a prospective, open-label trial 
performed in a single center. Written approval to carry 
out the study was received from the Institutional Review 
Board, and all subjects gave their informed consent to 
participate before the study commenced. This study 
recruited migraineurs with anxiety disorder. The 
following inclusion criteria were applied: (1) a diagnosis 
of migraine without aura according to the criteria of the 
International Headache Society 2004,
11  (2) conformance 
with the Diagnostic and Statistical Manual of Mental 
Disorders IV criteria for generalized anxiety disorder, (3) 
an initial Hamilton Anxiety Rating (HAM-A) score of 
18 or more, (4) age over 18 years, (5) the provision of 
signed assent, and (6) the ability to read and understand 
the self-reporting scales used in this study.
Subjects with the following history of conditions were 
excluded: (1) previously treated with paroxetine or an 
SSRI, (2) hepatitis or renal disease, as indicated by 
threefold elevations in the normal upper limits of GOT, 
GPT or bilirubin creatinine level > 2.0 mg/dl (176.7μ
mol/l) or receiving dialysis, (3) cardiovascular diseases, 
(4) surgical operation that can affect drug absorption or 
renders the patient unable to take oral medication, (5) 
disability or deficit, as assessed by a physical or 
neurological examination, (6) history of psychiatric 
disease, (7) prophylactic migraine medication that can 
influence a migraine attack within 4 weeks, (8) 
alcoholism or history of drug addiction, and (9) history 
of allergy or hypersensitivity to paroxetine.
Paroxetine was administered at a dosage of 20 in two 
divided doses for 12 weeks. The dosage was halved to 
10 mg twice a day if the subject reported side effects. 
If side effects persisted, the subject was withdrawn from 
the trial.
2. Evaluation of efficacies
During the initial visit, patients were screened and 
underwent a complete evaluation of their medical 
history, and laboratory testing. After a 4-week baseline 
period, patients were followed up every 4 weeks for up 
to 12 weeks. During this follow-up period, all patients 
completed a headache diary and other scales, from 
which efficacy scales such as headache frequency were 
calculated. Mean headache frequencies were monitored 
every 4 weeks. The responder rate, which was the 
primary efficacy outcome, was defined as the percentage 
of subjects showing a reduction of 50% or greater in the 
attack frequency at 3 months compared to the baseline 
headache frequency. The HAM-A,
12 Headache Disability 
Inventory (HDI),
13  and the Headache Management 
Self-Efficacy (HMSE) scale were assessed at every 
visit.
14,15 Secondary efficacy outcomes included changes 
in headache frequency and in the HAM-A score.
3. Statistical analysis
To minimize possible bias from the withdrawal of 
subjects from the study, the final observation of apatient 
that discontinued the study was carried forward to all 
subsequent assessment periods (last observation carried 
forward, LOCF). Comparisons of headache frequency, Journal of Clinical Neurology: Vol. 2, No. 4, 2006
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　 Baseline At 3
Patients (n) 24 21
Mean age, years 54.9±12.1 55.2±12.5
Sex (males/females) 8/16 7/14
HF 18.4±12.1 13.3±13.1 (ns)
HF (% of baseline) 100±0 % 51.9±41.7 %**
HAM-A 27.5±7.1 19.9±5.3**
HMSE 89.3±18.6 101.4±19.8*
HDI 34.9±28.5 26.8±25.9 (ns)
HF; headache frequency, HAM-A; Hamilton Anxiety Rating scale, HMSE;= Headache Management Self-Efficacy Scale, HDI; Headache 
Disability Inventory, ns; statistically not significant, *p<0.05 and **p<0.01 vs baseline. Data are mean±SD values
Table 1. Baseline characteristics and outcome variables
Figure 1. Monthly headache frequency after paroxetine 
administration. Headache frequency decreased to 49.1% of the 
baseline level at 3 following treatment with paroxetine (*p<0.01 
vs baseline, as assessed by paired t-test). mo = months.
HAM-A, and HMSE scores to baseline values were 
performed using the paired t-test. The correlation 
between headache frequency and HAM-A score was 
analyzed by bivariate correlation analysis. Statistical 
significance was accepted for probability values of 
p<0.05.
RESULTS
1. Demographic profiles
Twenty-four consecutive migraineurs who met the 
criteria for general anxiety disorders were included in 
this study (see Table 1). They were aged between 33 
and 74 years (54.9±12.1 years, mean±SD). The patients 
comprised 8 men and 16 women, and the mean age did 
not differ significantly with gender (males 51.6±15.1 
years, females 56.8±10.0 years; p=0.223). Two patients 
withdrew from the study at the second visit (at 2 
months) and one withdrew at the third visit (at 3 
months).
2. Changes in monthly headache frequency
The headache frequencies at baseline and at 1, 2, and 
3 months after treatment were 18.4±12.1, 15.2±12.1, 
13.8±13.0, and 13.3±13.1 attacks per month, respec-
tively. When the headache frequencies of each individual 
are expressed as percentage ratios relative to their own 
baseline headache frequencies, the mean headache 
frequencies at 1, 2, and 3 months after treatment were 
68.4±31.7%, 53.7±41.2%, and 51.9±41.7%, respectively 
(all p<0.01 vs baseline, paired t-test; Table 1 and Fig. 1). 
Accordingly, paroxetine induced a 48.1% reduction in 
headache frequency at 3 months compared to the 
baseline.
3. Changes in HAM-A, HDI, and HMSE scores
Paroxetine treatment resulted in an improvement in 
mean HAM-A score from 27.5±7.1 (baseline) to 
19.9±5.3 at 3 months (p<0.001). All HAM-A subscales 
exhibited uniform reductions (one-way ANOVA). 
HMSE scores were also improved from 89.3±18.6 Park HJ, et al. The Effect of Paroxetine on the Reduction of Migraine Frequency 
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Figure 2. Correlation between reduction in headache frequency 
and Hamilton Anxiety Rating (HAM-A) score. There was no 
direct correlation between headache frequency and HAM-A 
score (Pearson’s correlation coefficient=-0.196; p=0.422).
(baseline) to 101.4±19.8 at 3 months (p=0.044). However, 
the mean HDI score, which was 34.9±28.5 at baseline and 
26.8±25.9 at 3 months, appeared to be unaffected by 
paroxetine treatment (p=0.347).
4. Paroxetine responsiveness and anxiolytic effect
The headache responder rate was 58.8% in this study 
(responders vs nonresponders = 14 vs 10) when all 
subjects were analyzed on an LOCF basis. The initial 
HAM-A scores did not differ significantly between the 
responder and nonresponder groups (responders 27.1, 
nonresponders 28.1; p=0.752). The final HAM-A scores 
at 3 months also did not differ between responders and 
nonresponders (responders 18.6±4.9, nonresponders 21.8 
±5.5;  p=0.871).
Bivariate correlation analysis revealed no significant 
correlation between the reduction in headache frequency 
and the improvement in HAM-A score (Pearson’s 
correlation coefficient -0.196, p=0.422; Fig. 2) More-
over, there was no significant correlation between 
headache frequency reduction and either HDI or HMSE.
DISCUSSION
This open-label study investigated the preventive 
effect of paroxetine for migraine, and the correlation 
between its anxiolytic effect and this preventive effect. 
After the paroxetine treatment, there was a reduction in 
both the level of anxiety and the headache frequency. 
However, the reduction in anxiety level was not 
correlated with the reduction in the headache frequency. 
Accordingly, it is likely that at least two mechanisms 
contribute independently to the migraine-prophylactic 
and anxiolytic effects of paroxetine.
Anxiety is a well-known migraine-precipitating factor.
6,16 
Other psychiatric comorbidities, such as depression or 
panic disorder, have also been linked to migraine.
17,18 
Antidepressants such as TCAs, SSRIs, or SNRIs are 
effective in the prevention of migraine;
10 however, the 
mechanisms underlying their actions have not been 
clearly defined. Given that antidepressants usually exert 
anxiolytic effects and that migraine attacks can be 
precipitated by anxiety,
17,18 it can be readily hypo-
thesized that the improvement in anxiety levels is related 
to the reduction in the frequency of migraine attacks.
The results of this study are not consistent with the 
above hypothesis. The observed reduction in HAM-A 
score induced by paroxetine demonstrates the efficacy of 
paroxetine in reducing the anxiety levels of migraineurs. 
However, a comparison of anxiety levels between 
paroxetine responders vs nonresponders showed that 
initial anxiety levels did not predict the outcome of 
headache responsiveness. In addition, the degree of 
improvement in anxiety scores was not correlated with the 
reduction in headache frequency. Accordingly, migraine 
prophylaxis by paroxetine appears to be independent of its 
anxiolytic effect, and is likely to be mediated through a 
direct modulation of the serotonergic system.
10
Our previous study with buspirone, a serotonin 
(5-hydroxytryptamine, 5-HT) 1A agonist, also reported 
that the prophylactic effect on migraine is not related to 
the reduction in anxiety levels.
19 Our two studies also 
suggest that the effected reduction in anxiety is not 
sufficient to prevent migraine.
The serotonergic system has been implicated in the 
pathogenesis of migraine disorder. The key evidence 
implicating 5-HT in migraine includes increased urinary 
excretion of 5-hydroxyindoleacetic acid, which is the 
main metabolite of serotonin, and a rapid fall in platelet Journal of Clinical Neurology: Vol. 2, No. 4, 2006
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5-HT levels during a migraine attack.
20,21 Moreover, 
intravenously injected 5-HT alleviates reserpine-induced 
headache.
22  The main serotonergic systems in migraine 
pathophysiology are 5-HT1 and 5-HT2.
24 There are three 
subtypes of 5-HT2  receptors: A, B, and C. Some 
migraine-prevention drugs, such as methysergide, cypro-
heptadine, and pizotifen, are potent 5-HT2B  and 5-HT2C 
receptor antagonists, whereas metachlorophenylpiperazine, 
a 5-HT2B and 5-HT2C receptor agonist, can trigger 
migraine in susceptible individuals.
24,25 The effect of 
paroxetine in migraine is likely to be attributable to the 
potentiation of these various serotonergic systems via the 
inhibition of selective 5-HT reuptake. However, there 
are controversial conclusions from past trials of SSRIs in 
migraines that SSRIs are no more efficacious than 
placebo in patients with migraine.
10  Therefore, further 
studies are warranted.
One limitation of this study is its open-label design 
and the inclusion of only a small number of subjects. 
Given that a small sample size can cause false-negative 
results, the correlation between the headache respon-
siveness and the anxiolysis should be verified in a larger 
population. Furthermore, the efficacy of paroxetine in mi-
graine should be investigated in placebo-controlled trials.
In summary, our results suggest that paroxetine is 
effective for both migraine prevention and anxiolysis in 
migraineurs with anxiety, and that its effect on migraine 
prevention is not secondary to its anxiolytic effect. 
Given that this study is based on small populations and 
is an open-label design, further studies are warranted to 
elucidate the discrete mechanisms involved in its actions, 
as well as to establish the controversial effects of SSRI 
in migraine.
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